Dr. Faustman Research Update
Woo-hoo! From www.diabetesincontrol.com:
Update on Dr. Faustman's Research on Reversing Type 1 Diabetes
The Faustman Lab at Massachusetts General Hospital, run by Denise L. Faustman, MD, PhD, is moving rapidly through the clinical trial challenge to test and possibly establish a vaccine using a generic drug, Bacillus Calmette-Guérin (BCG) to reverse Type 1 diabetes.
The experiments have moved from mice to a clinical trial in humans, and the testing has passed every research milestone ahead of schedule -- an astonishing feat for any clinical research project. The Phase I safety trial in people with Type 1 diabetes is near completion. The next step is to find, in a Phase II study, the possible dose and frequency of administration of BCG vaccinations that will benefit patients with Type 1 diabetes.
What makes these trials unique? First, unlike other immunosuppressive therapies for autoimmune diseases that harm both healthy and disease-causing T-cells, this treatment appears to provide a way to achieve "targeted removal" of only autoimmune disease-causing cells. BCG works by causing the release of a natural protein in the body called tumor necrosis factor, or TNF. In mice, temporarily elevating TNF levels destroys the autoreactive T-cells, allowing the insulin-producing cells of the pancreas to regenerate and produce insulin. TNF in mice also elevates a good population of T-cells, thus restoring the immune system to near normal. In other words, the treatment literally reverses Type 1 diabetes, at least in a mouse model of diabetes. In laboratory experiments, TNF also destroys the autoreactive cells in human blood samples. TNF does not harm the normal, healthy T-cells that help fight infection, leaving the immune system intact.
The human clinical trials seek to expand these findings in human subjects. The BCG trial is also unique since BCG is a generic drug that has been used widely as a vaccine for more than 80 years in humans. Currently, BCG is used in small doses as a vaccine against tuberculosis, and it is used in larger doses as a bladder cancer therapy. Because it has been used for so long and in so many humans, the safety of this vaccine is well-established. This fact allows the trials to move more quickly through safety studies compared to clinical trials that test new drugs.
With a generic drug, it can move BCG to the public rapidly if the drug is indeed found to be safe and effective in patients with Type 1 diabetes. The phase I safety study is following the enrolled patients over months looking for changes in the T-cells and also testing the reliability of the blood tests for tracking disease-causing T-cells.
The BCG trial is one of the few translational studies in human testing where the animal data showed disease reversal in diabetic mice that had hyperglycemia, not just in mice with normal blood sugars and with a predisposition to diabetes. Therefore, this human trial at Mass General is designed to treat people with established Type 1 diabetes unlike most human testing that focuses only on not yet diabetic patients at risk for the disease or newly diagnosed diabetics with a short time period of high blood sugars.
Click here for more information in a special report.
Update on Dr. Faustman's Research on Reversing Type 1 Diabetes
The Faustman Lab at Massachusetts General Hospital, run by Denise L. Faustman, MD, PhD, is moving rapidly through the clinical trial challenge to test and possibly establish a vaccine using a generic drug, Bacillus Calmette-Guérin (BCG) to reverse Type 1 diabetes.
The experiments have moved from mice to a clinical trial in humans, and the testing has passed every research milestone ahead of schedule -- an astonishing feat for any clinical research project. The Phase I safety trial in people with Type 1 diabetes is near completion. The next step is to find, in a Phase II study, the possible dose and frequency of administration of BCG vaccinations that will benefit patients with Type 1 diabetes.
What makes these trials unique? First, unlike other immunosuppressive therapies for autoimmune diseases that harm both healthy and disease-causing T-cells, this treatment appears to provide a way to achieve "targeted removal" of only autoimmune disease-causing cells. BCG works by causing the release of a natural protein in the body called tumor necrosis factor, or TNF. In mice, temporarily elevating TNF levels destroys the autoreactive T-cells, allowing the insulin-producing cells of the pancreas to regenerate and produce insulin. TNF in mice also elevates a good population of T-cells, thus restoring the immune system to near normal. In other words, the treatment literally reverses Type 1 diabetes, at least in a mouse model of diabetes. In laboratory experiments, TNF also destroys the autoreactive cells in human blood samples. TNF does not harm the normal, healthy T-cells that help fight infection, leaving the immune system intact.
The human clinical trials seek to expand these findings in human subjects. The BCG trial is also unique since BCG is a generic drug that has been used widely as a vaccine for more than 80 years in humans. Currently, BCG is used in small doses as a vaccine against tuberculosis, and it is used in larger doses as a bladder cancer therapy. Because it has been used for so long and in so many humans, the safety of this vaccine is well-established. This fact allows the trials to move more quickly through safety studies compared to clinical trials that test new drugs.
With a generic drug, it can move BCG to the public rapidly if the drug is indeed found to be safe and effective in patients with Type 1 diabetes. The phase I safety study is following the enrolled patients over months looking for changes in the T-cells and also testing the reliability of the blood tests for tracking disease-causing T-cells.
The BCG trial is one of the few translational studies in human testing where the animal data showed disease reversal in diabetic mice that had hyperglycemia, not just in mice with normal blood sugars and with a predisposition to diabetes. Therefore, this human trial at Mass General is designed to treat people with established Type 1 diabetes unlike most human testing that focuses only on not yet diabetic patients at risk for the disease or newly diagnosed diabetics with a short time period of high blood sugars.
Click here for more information in a special report.
Replies to This Discussion
-
Permalink Reply by Stephanie Atkins on -
This is greattttt!!!! Its coming, I believe:) We all need to keep our heads up!!
-
Permalink Reply by Patricia on -
I am very excited about their work and how quickly they are moving forward. It also seems to be the only real solution that fixes the problem...faulty immune system. Everything else requires that I continue to be concerned that my own system will destroy or disable the treatment provided. Even if it did not...I would continue to attack other tissue. The inflammation response can attack inner ear, joints, etc. I cannot wait to see the results of Phase 1. How many of us have provided blood samples? I am thinking of making the trip back east to do so. I used to work at MGH and lived on the south shore:) Interestingly, Faustman was trained right here in my home town...where the first islet transplants were done. She is a neat and committed researcher. If anyone has personal experience w/ participating in the trials in any way...please share:)
-
Permalink Reply by Gerri on -
I asked friends & family to send donations to Dr. Faustman instead of birthday & holiday gifts.
So encouraging! Hoping this has implications for other autoimmune diseases as well.
-
Permalink Reply by Patricia on
-
Great idea:) I thought of having a fundraiser...maybe a Tu meetup here in St. Louis! Share stories, laugh, and put some sheckles in for both Tu and Dr. Faustman:) I really wish I was independently wealthy!! Ok...or JUST working!
-
Permalink Reply by Gerri on
-
Amazing that they haven't given the combo of losing Type 1 customers & that a generic drug is involved. Hmm, maybe her lab is safe since Type 1s are only 10-15% of their customer base.
-
Permalink Reply by Patricia on
-
I remember something to the effect...that she is watching her back. I know she got flack from other researchers and colleagues...even at MGH. I so admire her committment and tenacity...a true physician and scientist:)
-
Permalink Reply by etta amy on -
I've been a fan of Dr. Faustman for a long time. Thanks for posting this.
Advertisement
REsources
Groups
From the Diabetes Hands Foundation blog...
How do you measure the work of volunteers?
329,040 minutes, 329,040 moments so dear. 329,040 minutes — How do you measure, measure volunteers? In smileys, in tears shed, in counsel, in cups of coffee. In units, in carb counts, in laughter, in strife. In 329,040 minutes – how …Continue Reading
DHF Expands Board of Advisors
Diabetes Hands Foundation has always relied on partners and advisors to increase its understanding of the diabetes space, in order to better serve people touched by diabetes. Today this is as true as ever, as we proudly announce the expansion …Continue Reading
TuDiabetes Team
DHF STAFF
 Manny Hernandez(Co-Founder, Editor, has LADA)
|
DHF VOLUNTEERS
Lead Administrator
 Bradford (has type 1) |
Administrators
 Lorraine (mother of type 1) |
 Marie B (has type 1) |
|
|
|
|
|
|
LIKE us on Facebook
Spread the word
This site complies with the HONcode standard for trustworthy health information: verify here.
© 2013 A community of people touched by diabetes, run by the Diabetes Hands Foundation.
